Olivier Trédan
About
Olivier Trédan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Olivier Trédan has authored 234 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Oncology, 76 papers in Pulmonary and Respiratory Medicine and 56 papers in Cancer Research. Recurrent topics in Olivier Trédan's work include Cancer Treatment and Pharmacology (35 papers), Advanced Breast Cancer Therapies (33 papers) and Ovarian cancer diagnosis and treatment (32 papers). Olivier Trédan is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), Advanced Breast Cancer Therapies (33 papers) and Ovarian cancer diagnosis and treatment (32 papers). Olivier Trédan collaborates with scholars based in France, United States and Italy. Olivier Trédan's co-authors include Ian F. Tannock, Carlos M. Galmarini, Karishma Patel, Charles Dumontet, P. Sève, Mario Campone, Isabelle Ray‐Coquard, Jean‐Yves Blay, David Pérol and Sylvie Chabaud and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Olivier Trédan
216 papers receiving 7.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Olivier Trédan France | 39 | 4.4k | 2.4k | 2.2k | 1.7k | 973 | 234 | 7.8k | ||
| Gideon M. Blumenthal United States | 47 | 4.0k 0.9× | 2.6k 1.1× | 2.4k 1.1× | 1.3k 0.8× | 926 1.0× | 119 | 7.5k | ||
| Antonio Jimeno United States | 39 | 3.5k 0.8× | 1.4k 0.6× | 3.5k 1.6× | 1.3k 0.8× | 1.0k 1.1× | 169 | 7.2k | ||
| Steven J. Isakoff United States | 37 | 5.0k 1.1× | 2.0k 0.8× | 3.9k 1.8× | 2.8k 1.6× | 554 0.6× | 176 | 9.3k | ||
| Wells A. Messersmith United States | 52 | 5.3k 1.2× | 1.8k 0.7× | 4.3k 2.0× | 1.7k 1.0× | 1.1k 1.1× | 298 | 9.5k | ||
| Anish Thomas United States | 43 | 3.7k 0.8× | 2.9k 1.2× | 2.8k 1.3× | 983 0.6× | 926 1.0× | 161 | 8.5k | ||
| Shivaani Kummar United States | 47 | 3.5k 0.8× | 1.5k 0.6× | 3.3k 1.5× | 1.3k 0.7× | 820 0.8× | 296 | 7.0k | ||
| Nicolás André France | 50 | 2.8k 0.6× | 1.2k 0.5× | 4.1k 1.9× | 1.8k 1.0× | 882 0.9× | 264 | 8.6k | ||
| Glen J. Weiss United States | 44 | 3.1k 0.7× | 1.9k 0.8× | 4.2k 1.9× | 1.9k 1.1× | 681 0.7× | 209 | 7.9k | ||
| X. Cynthia United States | 46 | 5.0k 1.1× | 2.8k 1.1× | 3.1k 1.4× | 2.3k 1.3× | 983 1.0× | 251 | 8.8k | ||
| Zhengjia Chen United States | 51 | 3.1k 0.7× | 2.5k 1.0× | 2.4k 1.1× | 989 0.6× | 816 0.8× | 267 | 8.3k |
Countries citing papers authored by Olivier Trédan
Since
Specialization
Citations
This map shows the geographic impact of Olivier Trédan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Trédan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Trédan more than expected).
Fields of papers citing papers by Olivier Trédan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Olivier Trédan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Trédan. The network helps show where Olivier Trédan may publish in the future.
Co-authorship network of co-authors of Olivier Trédan
This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Trédan. A scholar is included among the top collaborators of Olivier Trédan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Trédan. Olivier Trédan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lambertini, Matteo, et al.. (2025). Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey. The Breast. 81. 104456–104456.
2.
Larrouquère, Louis, Pierre-Étienne Heudel, Érika Cosset, et al.. (2024). 251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis. ESMO Open. 9. 103272–103272.
3.
Grellard, Jean‐Michel, Elsa Kalbacher, Olivier Trédan, et al.. (2024). Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study. Gynecologic Oncology. 187. 139–144.
4.
Rugo, Hope S., Aditya Bardia, Frederik Marmé, et al.. (2023). Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 402(10411). 1423–1433.
5.
Poulard, Coralie, Julien Jacquemetton, Loay Kassem, et al.. (2023). Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα + breast cancer. EMBO Molecular Medicine. 15(8). e17248–e17248.
6.
Brahmi, Mehdi, Olivier Trédan, Nicolas Penel, et al.. (2023). Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.. Journal of Clinical Oncology. 41(16_suppl). 11545–11545.
7.
Gutierrez, Maya, Émilie Le Rhun, Olivier Trédan, et al.. (2022). Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro-Oncology. 25(2). 365–374.
8.
Falandry, Claire, Fanny Pommeret, Laurence Gladieff, et al.. (2022). Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. The Lancet Healthy Longevity. 3(3). e176–e185.
9.
Nassif, Elise F., Édouard Auclin, Rastilav Bahleda, et al.. (2021). TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers. 13(13). 3362–3362.
10.
Delrieu, Lidia, Jeff K. Vallance, Magali Morelle, et al.. (2019). Physical activity preferences before and after participation in a 6‐month physical activity intervention among women with metastatic breast cancer. European Journal of Cancer Care. 29(1). e13169–e13169.
11.
Delrieu, Lidia, Vincent Pialoux, Olivia Pérol, et al.. (2019). Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. JMIR mhealth and uhealth. 8(1). e12306–e12306.
12.
Gourdin, Nicolas, Selena Viganó, Christelle Machon, et al.. (2018). Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. Cancer Research. 78(13). 3604–3618.
13.
Bonneau, Claire, Gilles Paintaud, Olivier Trédan, et al.. (2018). Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. European Journal of Cancer. 95. 75–84.
14.
Cornet, Sébastien, et al.. (2016). Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. Molecular Cancer Therapeutics. 15(6). 1238–1247.
15.
Vanacker, Hélène, et al.. (2015). Tumeurs du sein luminales (récepteurs hormonaux positifs, HER2 négatives) au stade avancé : les nouvelles options thérapeutiques en 2015. Bulletin du Cancer. 102(6). S47–S52.
16.
Schmitt, Caroline, Isabelle Treilleux, Olivier Trédan, et al.. (2015). Envahissement ganglionnaire axillaire sans tumeur primitive mammaire retrouvée : à propos de 16cas issus d’une cohorte de 7770patientes. Gynécologie Obstétrique & Fertilité. 43(9). 588–592.
17.
Heudel, Pierre-Étienne, Paul Vilquin, Olivier Trédan, et al.. (2012). Mechanisms of resistance to endocrine therapies for breast cancer. Hormone Molecular Biology and Clinical Investigation. 9(2). 165–171.
18.
Duthey, Béatrice, Vanja Sisirak, Danièle Salaün, et al.. (2011). Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene. 31(30). 3516–3524.
19.
Labidi‐Galy, Sana Intidhar, Vanja Sisirak, Pierre Méeus, et al.. (2011). Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. Cancer Research. 71(16). 5423–5434.
20.
Trédan, Olivier, Agathe Bajard, Anne Meunier, et al.. (2009). Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective study. Clinical Nutrition. 29(2). 187–191.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gideon M. Blumenthal Breakdown of academic impact, for papers by Antonio Jimeno Breakdown of academic impact, for papers by Steven J. Isakoff Breakdown of academic impact, for papers by Wells A. Messersmith Breakdown of academic impact, for papers by Anish Thomas Breakdown of academic impact, for papers by Shivaani Kummar Breakdown of academic impact, for papers by Nicolás André Breakdown of academic impact, for papers by Glen J. Weiss Breakdown of academic impact, for papers by X. Cynthia Breakdown of academic impact, for papers by Zhengjia Chen